Market Outlook - Lale Akoner from eToro suggests that 2026 will see a rotation into small-cap stocks, advising diversification away from growth technology stocks towards consumer-sensitive stocks and banks [1][2] - Recent data from BofA indicates that customers have been selling equities and there are outflows from ETFs, but this is seen as a rotation within risk assets rather than a move away from them [1] - The anticipated rate-cutting cycle, end of quantitative tightening, and financial deregulation are expected to support risk assets [2] Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) - Lexicon Pharmaceuticals reported Q3 2025 revenue of $14.2 million, primarily from a $13.2 million licensing agreement with Novo Nordisk, with a narrowed net loss of $12.8 million or $0.04 per share compared to a loss of $64.8 million the previous year [9] - The company achieved key R&D milestones, including the completion of IND-enabling studies for its obesity candidate LX9851 and advancing its heart failure medication INPEFA into international markets [10] - Citi analyst Yigal Nochomovitz raised Lexicon's price target to $2.10 from $1.90, maintaining a Buy rating based on updated financial models [8] Strive Inc. (NASDAQ:ASST) - Strive Inc. reported an average upside potential of 90.02% and has been recognized as a fast-growing penny stock [11] - The company announced the acquisition of Semler Scientific, positioning itself as the 11th largest public corporate holder of Bitcoin with approximately 12,797.9 BTC [12] - In Q3 2025, Strive raised $762.6 million through PIPE financing and warrant exercises, establishing itself as a publicly traded Bitcoin treasury asset management firm [13]

后市展望： 主题驱动或将转向基本面驱动，但科技成长仍是主线。自春季行情启动以来，市场领涨板块始终以事件驱动的主题性方向为主，如商业 航天、脑机接口等。这些板块尽管远期前景较好，但由于短期缺乏业绩和基本面支撑，因此稳定性较差，一旦出现震荡波动幅度将会比较剧烈。行情进入 震荡阶段后，交易量将有所下降，市场或将重新聚焦业绩和基本面驱动的板块。但春季行情的主要驱动因素仍然是市场风险偏好的上升，因此领涨方向仍 以科技成长为主，后续行情的热点将转向有基本面支撑的科技成长板块。 可关注半导体、电池、AI硬件、创新药等。 指数延续窄幅震荡，科创板跌幅较大。 周四指数延续窄幅震荡，尽管大盘勉强收红，但主要分类指数表现分化，跌多涨少，科创50指数下跌超3%领 跌市场。上涨家数仅1800余家，下跌家数超过3500家。成交量继续放大，周四全天成交3.26万亿元。沪指在1月13日结束连阳进入震荡期后，调整幅度总 体比较温和，本周指数总体延续了窄幅震荡格局，热门板块有序轮动。 热点板块： 1月科技和原材料涨价方向占优，高股息可做左侧关注。1月市场迎来春季行情的启动，历年春季躁动行情，科技成长方向大概率占优。 结合短期催化剂，诸如商业航天 ...

Core Viewpoint - CSPC Pharmaceutical Group has entered into an agreement with UK drugmaker AstraZeneca to develop innovative long-acting peptide medicines targeting obesity and weight-related conditions [1] Company Summary - CSPC Pharmaceutical Group is collaborating with AstraZeneca, indicating a strategic move towards addressing the growing market for obesity treatments [1] - The partnership focuses on the development of innovative long-acting peptide medicines, which may enhance treatment options for patients suffering from obesity and related health issues [1] Industry Summary - The agreement highlights the increasing emphasis on innovative therapies in the pharmaceutical industry, particularly in the area of obesity management [1] - The collaboration reflects a broader trend in the industry towards partnerships aimed at leveraging expertise and resources to tackle significant health challenges [1]

股票简称：丰原药业 股票代码：000153 公告编号：2026-002 安徽丰原药业股份有限公司 关于公司补缴税款的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大遗 漏。 安徽丰原药业股份有限公司（下称"公司"）全资子公司蚌埠丰原涂山制药有限公司近期依据国家税收法 律法规的要求，对涉税事项开展自查，现将有关事项公告如下： 一、基本情况 经自查，公司全资子公司蚌埠丰原涂山制药有限公司应补缴税款及滞纳金合计1,656.09万元，其中：补 缴税款1,122.77万元，滞纳金533.32万元。截至本公告披露日，上述税款及滞纳金已全部缴纳。 二、对公司的影响及风险提示 根据《企业会计准则第28号--会计政策、会计估计变更和差错更正》相关规定，上述补缴税款及滞纳金 事项不属于前期会计差错，不涉及前期财务数据追溯调整。上述补缴税款及滞纳金将计入公司2025年当 期损益，对公司2025年度归属于上市公司股东的净利润的具体影响金额最终以会计师事务所审计数据为 准。本次补缴税款事项不会影响公司的正常经营，敬请广大投资者注意投资风险。 特此公告。 安徽丰原药业股份有限公司董事会 202 ...

Core Insights - The centralized drug procurement program in Shaanxi has been implemented, covering 216 specifications of 16 drug varieties, with an average price reduction of 51.46% [1][2] - The program is expected to save medical institutions in Shaanxi approximately 1.443 billion yuan in the first year [1] - The initiative aims to ensure a stable supply of drugs by allowing multiple companies to win bids, thus avoiding supply risks associated with single-source procurement [1] Group 1 - The procurement project is the first in Shaanxi to save over 1 billion yuan, with a focus on commonly used drugs for cardiovascular and digestive conditions [1] - A total of 202 companies participated in the bidding process, submitting 505 products, which enhances competition and ensures diverse supply [1] - For example, the price of a commonly used drug for liver disease was reduced by 4.11 yuan per unit, saving patients over 80 yuan per treatment course [1] Group 2 - The provincial government has issued execution documents to clarify responsibilities for all parties involved, ensuring timely and sufficient delivery of drugs [2] - The centralized procurement is part of broader healthcare reforms aimed at reducing inflated drug prices and improving the market environment [2] - Shaanxi plans to continue optimizing drug procurement during the 14th Five-Year Plan, expanding the range of covered products to benefit more residents [2]

Core Viewpoint - Recordati has entered into a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational product for treating propionic acidemia, leveraging Moderna's mRNA technology and Recordati's commercial infrastructure [1][6]. Group 1: Collaboration Details - The agreement allows Moderna to lead the development of mRNA-3927, while Recordati will handle global commercialization if the product is approved [1]. - Recordati will pay Moderna an upfront payment of USD 50 million, with potential additional payments of up to USD 110 million based on development and regulatory milestones [4]. - The transaction is subject to customary closing conditions, including U.S. antitrust clearance expected within 30 days [5]. Group 2: Product Information - mRNA-3927 aims to restore propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia, a rare inherited metabolic disorder characterized by toxic metabolite buildup [2][7]. - Interim clinical data published in Nature indicates early signs of clinical improvement, with a potential data readout expected by the end of 2026 [3][10]. - mRNA-3927 is designed as a targeted disease-modifying therapy and is currently in a registrational clinical study to reduce metabolic decompensation events [3][10]. Group 3: Market Context - Propionic acidemia affects approximately 1 in 100,000-150,000 individuals globally and currently lacks effective therapies targeting the disease's root cause [7]. - The collaboration aims to address the significant unmet medical need for disease-modifying treatment options in this patient population [6].

Core Viewpoint - Recordati has entered into a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational product for treating propionic acidemia, leveraging Moderna's mRNA technology and Recordati's commercial infrastructure [1][6]. Group 1: Collaboration Details - The agreement stipulates that Recordati will pay Moderna an upfront payment of USD 50 million, with potential additional payments of up to USD 110 million based on development and regulatory milestones [4]. - Recordati will lead global commercialization efforts if mRNA-3927 is approved, while Moderna will continue to lead its development [1][4]. Group 2: Product Overview - mRNA-3927 is designed to restore propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia, a rare inherited metabolic disorder characterized by toxic metabolite buildup [2][9]. - Interim clinical data published in Nature indicates early signs of clinical improvement, with a potential data readout expected by the end of 2026 [3][10]. Group 3: Market Context - Propionic acidemia affects approximately 1 in 100,000-150,000 individuals globally and currently lacks effective therapies targeting the underlying cause [7]. - If approved, mRNA-3927 could be the first disease-modifying treatment option available for this severe condition [2][6]. Group 4: Company Background - Recordati is an international pharmaceutical group with a focus on specialty and primary care, operating in around 150 countries and employing over 4,500 people [11]. - The company aims to address both common health challenges and rare diseases, emphasizing the belief that health is a fundamental right [11].

Core Viewpoint - Moderna has entered a strategic collaboration with Recordati to advance its investigational therapeutic mRNA-3927 for propionic acidemia through clinical development and global commercialization [1] Group 1: Collaboration Details - Moderna will lead the clinical development and manufacturing of mRNA-3927 [1] - The collaboration will provide Moderna with up to $160 million in upfront and near-term development and regulatory milestones [1] - Additional financial incentives include commercial and sales milestones, as well as tiered royalties on net sales [1] Group 2: Partner Information - Recordati is an international pharmaceutical group based in Milan, Italy [1] - The company specializes in treatments for specialty and primary care, as well as rare diseases, including propionic acidemia [1]

It's time for earning season again. Happy 2026. We're back and I'm bringing you those must-see earnings charts.Now, I've decided not to do the MAG 7 this earnings season because they're being covered in a whole bunch of other places. I just covered the MAG7 on the Zachs Market Edge podcast, for instance. So, you can go over there and check out all those charts.uh we'll all still be watching them, but there's other stocks that are equally as important this earning season, and I brought some of them for you f ...

Core Viewpoint - BioSyent Inc. has declared a quarterly dividend of $0.055 per common share, marking a 10% increase from the previous quarter's dividend of $0.05 per share, reflecting the company's commitment to returning value to shareholders [1]. Company Overview - BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol "RX". The company focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record of improving patient lives [2]. - The company supports healthcare professionals by marketing its products through community, specialty, and international business units [2]. Financial Information - As of the date of the press release, BioSyent has 11,263,255 common shares outstanding [3].